| ASSET | QUARTER | % RETURN |
|---|---|---|
Better Choice (BTTR) | Q2 2014 | 43,900% |
NioCorp Developments Ltd Common Stock (NB) | Q2 2014 | 168% |
Cyclo Therapeutics (CYTH) | Q2 2014 | 163.51% |
Ontrak (OTRK) | Q2 2014 | 144.05% |
Quest Resource (QRHC) | Q2 2014 | 136.82% |
RadNet (RDNT) | Q2 2014 | 131.01% |
Immunic (IMUX) | Q2 2014 | 122.37% |
Quantum Computing (QUBT) | Q2 2014 | 119.35% |
Theravance Biopharma (TBPH) | Q2 2014 | 116.14% |
Interlink Electronics (LINK) | Q2 2014 | 116% |
Xcel Brands (XELB) | Q2 2014 | 113.33% |
VistaGen Therapeutics (VTGN) | Q2 2014 | 107.12% |
Socket Mobile (SCKT) | Q2 2014 | 106.87% |
ENGlobal (ENG) | Q2 2014 | 100% |
InMed Pharmaceuticals (INM) | Q2 2014 | 96.19% |
Tuniu (TOUR) | Q2 2014 | 95.89% |
Sypris Solutions (SYPR) | Q2 2014 | 94.47% |
Willdan (WLDN) | Q2 2014 | 88.48% |
Nephros (NEPH) | Q2 2014 | 84.38% |
Repligen (RGEN) | Q2 2014 | 76.8% |
India Globalization Capital (IGC) | Q2 2014 | 75.31% |
INVO Bioscience (INVO) | Q2 2014 | 75% |
NAYA Biosciences (NAYA) | Q2 2014 | 75% |
Fennec Pharmaceuticals (FENC) | Q2 2014 | 74% |
EDAP TMS (EDAP) | Q2 2014 | 71.72% |
